Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Pediatr. Aug 8, 2013; 2(3): 16-25
Published online Aug 8, 2013. doi: 10.5409/wjcp.v2.i3.16
Potential for treatment of severe autism in tuberous sclerosis complex
Tanjala T Gipson, Gwendolyn Gerner, Mary Ann Wilson, Mary E Blue, Michael V Johnston
Tanjala T Gipson, Gwendolyn Gerner, Michael V Johnston, Tuberous Sclerosis Clinic, Kennedy Krieger Institute, Baltimore, MD 21205, United States
Tanjala T Gipson, Gwendolyn Gerner, Michael V Johnston, Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, MD 21205, United States
Tanjala T Gipson, Gwendolyn Gerner, Michael V Johnston, Clinical Trials Unit, Kennedy Krieger Institute, Baltimore, MD 21205, United States
Mary Ann Wilson, Mary E Blue, Michael V Johnston, Neuroscience Laboratory, Hugo W. Moser Research Institute, Inc., Kennedy Krieger Institute, Baltimore, MD 21205, United States
Mary Ann Wilson, Mary E Blue, Michael V Johnston, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
Mary Ann Wilson, Mary E Blue, Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
Michael V Johnston, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
Michael V Johnston, Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States
Author contributions: Gipson TT, Gerner G, Wilson MA, Blue ME and Johnston MV solely contributed to this paper.
Supported by Grant 2K12NS001696-11A1 (to Gipson TT) from the National Institute of Neurological Disorders and Stroke; Grant 5T32HD007414-18 (to Gerner G) from the National Institute of Child Health and Human Development
Correspondence to: Tanjala T Gipson, MD, Tuberous Sclerosis Clinic, Kennedy Krieger Institute, 716 North Broadway, Baltimore, MD 21205, United States. gipson@kennedykrieger.org
Telephone: +1-443-9232746 Fax: +1-443-9239165
Received: February 22, 2013
Revised: May 26, 2013
Accepted: June 1, 2013
Published online: August 8, 2013
Processing time: 125 Days and 8.8 Hours
Core Tip

Core tip: Children with severe behaviors and cognitive impairment may benefit from newly available mechanism-based treatments; however, several factors warrant consideration in clinical trial design and implementation.